Sam Boong Park Sells 3,403 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) COO Sam Boong Park sold 3,403 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $20,690.24. Following the completion of the transaction, the chief operating officer now directly owns 254,826 shares in the company, valued at $1,549,342.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sight Sciences Stock Down 3.2 %

Shares of SGHT opened at $5.81 on Friday. The business’s fifty day moving average price is $6.50 and its two-hundred day moving average price is $6.23. The firm has a market capitalization of $289.08 million, a price-to-earnings ratio of -5.19 and a beta of 2.71. Sight Sciences, Inc. has a 52 week low of $1.04 and a 52 week high of $8.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $21.37 million for the quarter, compared to analysts’ expectations of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same quarter last year, the business earned ($0.30) earnings per share. On average, analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Sight Sciences by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after buying an additional 81,768 shares during the last quarter. Long Focus Capital Management LLC raised its position in shares of Sight Sciences by 86.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock valued at $3,739,000 after acquiring an additional 260,594 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Sight Sciences by 25.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after acquiring an additional 76,549 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Sight Sciences in the 2nd quarter valued at $1,234,000. Finally, RTW Investments LP bought a new position in shares of Sight Sciences in the 4th quarter worth $850,000. Institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Morgan Stanley boosted their price objective on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Lake Street Capital initiated coverage on shares of Sight Sciences in a research report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Friday, August 2nd. Finally, Citigroup raised their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a research report on Wednesday, July 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.25.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.